Conceptional considerations for a German influenza pandemic preparedness plan

Medical Microbiology and Immunology

Volumn 191, Issue 3-4, 2002, Pages 191-195

  Fock, R ^a   Bergmann, H ^b   Bussmann, H ^c   Fell, G ^d   Finke, E J ^e   Koch, U ^f   Niedrig, M ^a   Peters, M ^g   Scholz, D ^h   Wirtz, A ⁱ  

^a ROBERT KOCH INSTITUTE   (Germany)

^b BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

^c Social Service and Health   (Germany)

^d Dr Brill Partner GmbH Institute for Hygiene and Microbiology   (Germany)

^e Sanitatsakademie der Bundeswehr   (Germany)

^f Dist Admin South West Pfalz   (Germany)

^g Public Health Department   (Germany)

^h Sanitatsamt der Bundeswehr   (Germany)

ⁱ Hessian Ministry for Social Service   (Germany)

Author keywords

Disaster prevention; Influenza; Pandemic; Preparedness plan; Public health

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; RIMANTADINE; SIALIDASE INHIBITOR;

CHEMOPROPHYLAXIS; COMPETENCE; DECISION MAKING; EPIDEMIC; ETHICS; GERMANY; HAEMOPHILUS INFLUENZAE; HEALTH; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A; LOBAR PNEUMONIA; MEDICAL CARE; MENINGITIS; PLANNING; POPULATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SOCIAL ASPECT; VACCINE PRODUCTION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; GERMANY; HEALTH PLANNING; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMONIA, PNEUMOCOCCAL; VACCINATION;

EID: 0036456069     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-002-0145-y     Document Type: Review

References (16)

1. Centers for Disease Control, National Vaccine Program Office (2001) Pandemic Influenza: A Planning Guide for State and Local Officials (Draft 2.1). http://www.cdc.gov/od/nvpo/pandemic-flu.htm
2. Clausen L, Drombrowsky WR, Strangmeier RLF (1995) Deutsche regelsysteme. Vernetzungen und integrationsdefizite bei der erstellung des öffentlichen gutes zivil- und katastro-phenschutz in Europa. In: Bundesamt für Zivilschutz (ed) Zivilschutz-Forschung. Neue Folge Band 18. Schriftenreihe der Schutzkommission beim Bundesministerium des Innern, Bonn
3. Collins SD (1931) Age and sex incidence of influenza and pneumonia morbidity and mortality in the epidemic of 1928-1929 with comparative data for the epidemic of 1918-1919. Public Health Rep 46:1909-1937
4. Couch RB (2000) Drug therapy: Prevention and treatment of influenza. N Engl J Med 343:1778-1787
5. De Bock V, Peters P, Planta TA van, Gibbens M, Ward P (2000). Oseltamivir for prevention of influenza in the frail elderly. Clin Microbiol Infect 6:S140
6. Fock R, Bergmann H, Bussmann H, Fell G, Finke EJ, Koch U, Peters M, Scholz D, Wirtz A (2001) Management und kontrolle einer influenzapandemie. Konzeptionelle uberlegungen für einen deutschen influenzapandemieplan. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44:969-980
7. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG, the Oseltamivir Study Group (1999). Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336-1343
8. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM, Sharp SJ, Ossi MJ, for the Zanamivir Family Study Group (2000) Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 343:1282-1289
9. Monto AS, Fendrick AM (2000) Developments in influenza prevention and treatment. A managed care perspective. Dis Manage Health Outcomes 7:235-243
10. Monto AS, Robinson DP, Herlocher, ML, Hinson, JM, Elliott MJ, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults. A randomised controlled trial. JAMA 282:31-35
11. Robert Koch-Institut (2001) Expertenworkshop Influenzapandemie, Potsdam, 28./29. Mai 2001. Ergebnisprotokoll
12. Scholtissek C, Webster RG (1998) Long-term stability of the anti-influenza A compounds amantadine and rimantadine. Antiviral Res 38:213-215
13. Ständige Impfkommission am Robert Koch-Institut (2001) Impfempfehlungen der ständigen impfkommission (STIKO) am Robert Koch-Institut. Stand Juli 2001. Epidemiol. Bull. 28:203-218
14. Szucs T, Behrens M, Volmer T (2001) Volkswirtschaftliche kosten der influenza 1996. Eine krankheitskostenstudie. Med Klin 96:63-70
15. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS for the Oseltamaivir Post Exposure Prophylaxis Investigator Group (2001) Effectiveness of oseltamivir in preventing influenza in household contacts. A randomized controlled trial. JAMA 285:748-754
16. WHO (1999) Influenza Pandemic Preparedness Plan. Responding to an Influenza Pandemic or its Threat: The Role of WHO and Guidelines for National or Regional Planning. http:// www.who.int/emc-documents/influenza/docs/whocdscs-redc991.pdf